Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study

Hypertension

Volumn 66, Issue 3, 2015, Pages 563-570

  Van Ballegooijen, Adriana J ^a   Gansevoort, Ron T ^b   Lambers Heerspink, Hiddo J ^b   De Zeeuw, Dick ^b   Visser, Marjolein ^a   Brouwer, Ingeborg A ^a   Kema, Ido P ^b   De Borst, Martin H ^b   Bakker, Stephan J L ^b,c   Joosten, Michel M ^b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

1,25 dihydroxyvitamin D; 25 hydroxyvitamin D; blood pressure; hypertension; parathyroid hormone; risk factors; seasonal variation

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; PARATHYROID HORMONE; 1,25-DIHYDROXYVITAMIN D; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEASONAL VARIATION; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; INCIDENCE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PHYSIOLOGY; RISK;

ADULT; AGED; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; VITAMIN D;

EID: 84939233981     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05837     Document Type: Article

References (30)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219. doi: 10.1093/eurheartj/eht151.
2. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063-1069. doi: 10.1161/HYPERTENSIONAHA.107.087288.
3. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828-832. doi: 10.1161/HYPERTENSIONAHA.108.117630.
4. Margolis KL, Martin LW, Ray RM, Kerby TJ, Allison MA, Curb JD, Kotchen TA, Liu S, Wassertheil-Smoller S, Manson JE; Women's Health Initiative Investigators. A prospective study of serum 25-hydroxyvitamin D levels, blood pressure, and incident hypertension in postmenopausal women. Am J Epidemiol. 2012;175:22-32. doi: 10.1093/aje/kwr274.
5. Ke L, Graubard BI, Albanes D, Fraser DR, Weinstein SJ, Virtamo J, Brock KE. Hypertension, pulse, and other cardiovascular risk factors and vitamin D status in Finnish men. Am J Hypertens. 2013;26:951-956. doi: 10.1093/ajh/hpt051.
6. van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, Ix JH, Visser M, Brouwer IA. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:1214-1222. doi: 10.1016/j.jacc.2014.01.012.
7. Prentice A, Goldberg GR, Schoenmakers I. Vitamin D across the lifecycle: physiology and biomarkers. Am J Clin Nutr. 2008;88:500S-506S.
8. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 1979;64:729-736. doi: 10.1172/JCI109516.
9. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4-8. doi: 10.1016/j.pbiomolbio.2006.02.016.
10. Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26:1390-1394. doi: 10.1097/ HJH.0b013e3282ffb43b.
11. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000;11:1882-1888.
12. Agborsangaya C, Toriola AT, Grankvist K, Surcel HM, Holl K, Parkkila S, Tuohimaa P, Lukanova A, Lehtinen M. The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione. Nutr Cancer. 2010;62:51-57. doi: 10.1080/01635580903191460.
13. Bodnar LM, Catov JM, Wisner KL, Klebanoff MA. Racial and seasonal differences in 25-hydroxyvitamin D detected in maternal sera frozen for over 40 years. Br J Nutr. 2009;101:278-284. doi: 10.1017/ S0007114508981460.
14. Joosten MM, Gansevoort RT, Mukamal KJ, Kootstra-Ros JE, Feskens EJ, Geleijnse JM, Navis G, Bakker SJ; PREVEND Study Group. Urinary magnesium excretion and risk of hypertension: the prevention of renal and vascular end-stage disease study. Hypertension. 2013;61:1161-1167. doi: 10.1161/HYPERTENSIONAHA.113.01333.
15. Oterdoom LH, Gansevoort RT, Schouten JP, de Jong PE, Gans RO, Bakker SJ. Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis. 2009;207:534-540. doi: 10.1016/j. atherosclerosis.2009.05.010.
16. Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, de Zeeuw D, de Jong PE; PREVEND Study Group. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004;256:324-330. doi: 10.1111/j.1365-2796.2004.01390.x.
17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20-29. doi: 10.1056/ NEJMoa1114248.
18. Sachs MC, Shoben A, Levin GP, Robinson-Cohen C, Hoofnagle AN, Swords-Jenny N, Ix JH, Budoff M, Lutsey PL, Siscovick DS, Kestenbaum B, de Boer IH. Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2013;97:1243-1251. doi: 10.3945/ ajcn.112.054502.
19. de Boer IH, Sachs MC, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab. 2012;97:4780-4788. doi: 10.1210/jc.2012-2852.
20. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340-1349. doi: 10.1001/archinte.168.12.1340.
21. Christensen MH, Lien EA, Hustad S, Almås B. Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scand J Clin Lab Invest. 2010;70:281-286. doi: 10.3109/00365511003797172.
22. Vanderschueren D, Pye SR, O'Neill TW, et al; EMAS Study Group. Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middleaged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2013;98:995-1005. doi: 10.1210/jc.2012-2772.
23. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543-1551. doi: 10.1016/S0140-6736(10)61032-X.
24. Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension. 2014;64:1005-1011. doi: 10.1161/ HYPERTENSIONAHA.114.03748.
25. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307:674-684. doi: 10.1001/jama.2012.120.
26. Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW, Yu CM. Effect of paricalcitol on left ventricular mass and function in CKD-the OPERA trial. J Am Soc Nephrol. 2014;25:175-186. doi: 10.1681/ASN.2013010103.
27. Scragg R, Slow S, Stewart AW, Jennings LC, Chambers ST, Priest PC, Florkowski CM, Camargo CA Jr, Murdoch DR. Long-term high-dose vitamin D3 supplementation and blood pressure in healthy adults: a randomized controlled trial. Hypertension. 2014;64:725-730. doi: 10.1161/ HYPERTENSIONAHA.114.03466.
28. Pilz S, Gaksch M, Kienreich K, et al. Effects of vitamin d on blood pressure and cardiovascular risk factors: a randomized controlled trial. Hypertension. 2015;65:1195-1201. doi: 10.1161/HYPERTENSIONAHA.115.05319.
29. Cosman F, Shen V, Morgan D, Gordon S, Parisien M, Nieves J, Lindsay R. Biochemical responses of bone metabolism to 1,25-dihydroxyvitamin D administration in black and white women. Osteoporos Int. 2000;11:271-277. doi: 10.1007/s001980050292.
30. Richart T, Li Y, Staessen JA. Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens. 2007;20:1007-1015. doi: 10.1016/ j.amjhyper.2007.03.017.